Zai starts Chinese Phase III of Zejula for SCLC

Zai Lab Ltd. (NASDAQ:ZLAB) began a double-blind, placebo-controlled, Chinese Phase III trial to evaluate Zejula niraparib in 591 small cell lung cancer (SCLC) patients who have responded to platinum-based chemotherapy.

Zejula is approved in the U.S. and EU as maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy...